Vaginal and oral use of probiotics as adjunctive therapy to fluconazole in patients with vulvovaginal candidiasis: A clinical trial on Iranian women

Q3 Medicine
Z. Vahedpoor, M. Abastabar, M. Sehat, P. Talebian, Tayebeh Felfelian fini, Zahra Dastanpour, I. Haghani, Ramtin Chelongarian, M. Nazeri
{"title":"Vaginal and oral use of probiotics as adjunctive therapy to fluconazole in patients with vulvovaginal candidiasis: A clinical trial on Iranian women","authors":"Z. Vahedpoor, M. Abastabar, M. Sehat, P. Talebian, Tayebeh Felfelian fini, Zahra Dastanpour, I. Haghani, Ramtin Chelongarian, M. Nazeri","doi":"10.18502/cmm.7.3.7803","DOIUrl":null,"url":null,"abstract":"Background and Purpose: Vulvovaginal candidiasis is considered the second most prevalent gynecologic infection among women and one of the main reasons for referring to a gynecologist. During recent decades, probiotic usage has been defined as one of the therapeutic regimens for vaginal candidiasis management, but these findings were controversial. The current study was conducted to determine the effect of fluconazole plus vaginal and oral probiotics supplementation on clinical and mycological improvement of vaginal candidiasis concomitant with antifungal susceptibility of Candida species to fluconazole. Materials and Methods: This double-blind, randomized, placebo-controlled trial was conducted on 76 women with vaginal candidiasis admitted to Naghavi and Imam Reza Gynecology Clinics in Kashan, Central Iran, from July 2017 to March 2020. Patients were diagnosed according to vaginal candidiasis symptoms and positive culture for Candida species. The patients were divided into two groups; one of them received fluconazole plus vaginal and oral probiotics, while the other one received fluconazole with placebo. The clinical and mycological findings were recorded before and after the treatment. In vitro, the fluconazole susceptibility test was determined by the microdilution method according to the Clinical and Laboratory Standards Institute (M27-A3) for the baseline Candida isolates. Conclusion: Based on the findings, 35 days after the intervention, a significant reduction was reported in vaginal candidiasis symptoms in the probiotics supplementation group. Although probiotics supplementation therapy was a better mycological cure, compared to the fluconazole with the placebo group, this difference was not significant (68.4% vs. 46.9%, P=0.184). Exclusion of resistant and susceptible dose-dependent strain in the regression model demonstrated a significant reduction in positive culture probiotics in the supplementation group. Results: Oral and vaginal supplementation with probiotics for 4 weeks played a significant role in the elimination of vaginal candidiasis symptoms. Adjustment of clinical and mycological responses with drug resistance patterns of patients could open a promising horizon for probiotics consumption as a complementary treatment.","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"39 1","pages":"36 - 43"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Mycology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/cmm.7.3.7803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Background and Purpose: Vulvovaginal candidiasis is considered the second most prevalent gynecologic infection among women and one of the main reasons for referring to a gynecologist. During recent decades, probiotic usage has been defined as one of the therapeutic regimens for vaginal candidiasis management, but these findings were controversial. The current study was conducted to determine the effect of fluconazole plus vaginal and oral probiotics supplementation on clinical and mycological improvement of vaginal candidiasis concomitant with antifungal susceptibility of Candida species to fluconazole. Materials and Methods: This double-blind, randomized, placebo-controlled trial was conducted on 76 women with vaginal candidiasis admitted to Naghavi and Imam Reza Gynecology Clinics in Kashan, Central Iran, from July 2017 to March 2020. Patients were diagnosed according to vaginal candidiasis symptoms and positive culture for Candida species. The patients were divided into two groups; one of them received fluconazole plus vaginal and oral probiotics, while the other one received fluconazole with placebo. The clinical and mycological findings were recorded before and after the treatment. In vitro, the fluconazole susceptibility test was determined by the microdilution method according to the Clinical and Laboratory Standards Institute (M27-A3) for the baseline Candida isolates. Conclusion: Based on the findings, 35 days after the intervention, a significant reduction was reported in vaginal candidiasis symptoms in the probiotics supplementation group. Although probiotics supplementation therapy was a better mycological cure, compared to the fluconazole with the placebo group, this difference was not significant (68.4% vs. 46.9%, P=0.184). Exclusion of resistant and susceptible dose-dependent strain in the regression model demonstrated a significant reduction in positive culture probiotics in the supplementation group. Results: Oral and vaginal supplementation with probiotics for 4 weeks played a significant role in the elimination of vaginal candidiasis symptoms. Adjustment of clinical and mycological responses with drug resistance patterns of patients could open a promising horizon for probiotics consumption as a complementary treatment.
阴道和口服益生菌作为外阴阴道念珠菌病患者氟康唑的辅助治疗:一项针对伊朗妇女的临床试验
背景与目的:外阴阴道念珠菌病被认为是女性第二大常见妇科感染,也是妇科就诊的主要原因之一。近几十年来,益生菌的使用已被定义为阴道念珠菌病管理的治疗方案之一,但这些发现存在争议。本研究旨在确定氟康唑加阴道和口服益生菌对阴道念珠菌病临床和真菌学改善的影响,同时念珠菌对氟康唑具有抗真菌敏感性。材料与方法:该双盲、随机、安慰剂对照试验于2017年7月至2020年3月在伊朗中部卡尚Naghavi和Imam Reza妇科诊所就诊的76名阴道念珠菌病女性进行。根据阴道念珠菌病的症状和念珠菌培养阳性进行诊断。患者分为两组;其中一组服用氟康唑加阴道和口服益生菌,另一组服用氟康唑加安慰剂。记录治疗前后的临床及真菌学表现。体外根据临床与实验室标准协会(M27-A3)微量稀释法对基线念珠菌分离株进行氟康唑药敏试验。结论:根据研究结果,干预后35天,益生菌补充组阴道念珠菌病症状显着减少。虽然与氟康唑和安慰剂组相比,益生菌补充治疗是更好的真菌学治疗,但这种差异并不显著(68.4%对46.9%,P=0.184)。在回归模型中排除耐药和敏感的剂量依赖菌株表明,补充组的阳性培养益生菌显著减少。结果:口服和阴道补充益生菌4周对阴道念珠菌病症状的消除有显著作用。随着患者耐药模式的调整,临床和真菌学反应为益生菌消费作为补充治疗开辟了广阔的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Mycology
Current Medical Mycology Medicine-Infectious Diseases
CiteScore
2.10
自引率
0.00%
发文量
16
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信